FindTrial
Sign In

Asymmetric dimethylarginine is associated with CHA2DS2-VASc scores in nonvalvular atrial fibrillation patients

Asymmetric dimethylarginine is associated with CHA2DS2-VASc scores in nonvalvular atrial fibrillation patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074043
Enrollment
Unknown
Registered
2023-07-28
Start date
2023-07-29
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arrhythmias

Interventions

Divide into two groups based on the CHA2DS2-VASc score:NA

Sponsors

No. 5 Donghai Middle Road, Shinan District, Qingdao, Shandong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to No maximum

Inclusion criteria

Inclusion criteria: Age greater than 35 years with a diagnosis of nonvalvular atrial fibrillation

Exclusion criteria

Exclusion criteria: Exclusion Criteria: patients with malignant tumors, hematologic disorders, hepatic or renal insufficiency, pregnancy, or infections, and exclusion of subjects with valvular disorders, including rheumatic heart disease, prosthetic heart valves or previous valve repairs, and moderate to severe mitral or aortic stenosis or regurgitation.

Design outcomes

Primary

MeasureTime frame
ADMA;—

Secondary

MeasureTime frame
p-sel;PAI-1;von Willebrand Factor, vWF;D-Di;—

Countries

China

Contacts

Public ContactWei Xia

Department of Cardiology, East Hospital District, Qingdao Municipal Hospital

summer0419@163.com+86 186 6971 0958

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026